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Abstract 
Background and Aims:  EUS and endoscopic pancreatic function tests (ePFTs) may be used to diagnose 
minimal- change chronic pancreatitis (MCCP).  The impact of evaluation for exocrine pancreatic 
insufficiency (EPI) and real-time assessment of EUS changes after intravenous secretin on the clinical 
diagnosis of MCCP is unknown.   
Methods: Patients with suspected MCCP underwent baseline EUS assessment of the pancreatic
parenchyma and measurement of the main pancreatic duct (B-MPD) in the head, body, and tail.  
Human secretin 0.2 µg/kg IV was given followed 4, 8, and 12 minutes later by repeat MPD (S-MPD) 
measurements. Duodenal samples at 15, 30, and 45 minutes were aspirated for bicarbonate 
concentration.  Endoscopists rated the percent clinical likelihood of CP: (1) before secretin; (2) after 
secretin but before aspiration; and (3) after bicarbonate results.  
Results: 145 consecutive patients (mean age 44±13 years; 98F) were diagnosed with EPI (n=32; 22%).  S-
MPD/B-MPD ratios in the tail 4 and 8 minutes after secretin were higher in the group with normal 
exocrine function. Ratios at other times, locations and duodenal fluid volumes were similar between 
the 2 groups.  A statistically significant change in the median percent likelihood of CP was noted after 
secretin in all groups.  The sensitivity and specificity of EPI for the EUS diagnosis of CP (≥5 criteria) were 
23.4% (95% CI, 12.3-38.0) and 78.6% (95% CI, 69.1-86.2), respectively. 
Conclusion: Real-time EUS findings and ePFTs have a significant impact on the clinical assessment of 
MCCP. The diagnosis of EPI shows poor correlation with the EUS diagnosis of MCCP. 
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Introduction 
Chronic pancreatitis is an irreversible, fibrosing disease caused most commonly by chronic alcohol or 
tobacco use, genetic predisposition and recurrent acute pancreatitis.
1
 Symptoms almost always include 
pain and later exocrine pancreatic insufficiency (EPI) with malabsorption may occur with progressive 
fibrosis.  The diagnosis of chronic pancreatitis with extensive calcifications, gland atrophy or 
pancreatolithiasis is relatively straightforward. However, early or “minimal-change” chronic pancreatitis 
(MCCP) is more difficult to detect due to the often lack of radiologic findings, laboratory parameters and 
classic symptomatology.  Additional diagnostic tools to permit accurate early detection before extensive 
fibrosis of the pancreas would be a major advance. 
 
The use of endoscopic ultrasound (EUS) for the diagnosis of chronic pancreatitis has historically used 
parenchymal and ductal abnormalities
2,3
 with diagnostic certainty increasing as more abnormalities are 
identified.  More recently, the Rosemont classification was proposed giving greater weight to some EUS 
features and assigned major and minor criteria for the diagnosis.
4
   However, the use of EUS for 
diagnosing chronic pancreatitis does have some limitations. First, it is generally accepted that ≥5 EUS 
features maximizes specificity for the diagnosis but certainty remains less clear in patients with fewer 
features.
2-6
  Second, although EUS findings are speculatively correlated with a histological abnormality, it 
is unclear which feature is pathologic or seen in normal human aging.
7,8
  Third, the relative value of 
assigning more importance to any EUS criteria remains doubtful over the traditional scoring system.
9
  
Finally, interobserver agreement for the diagnosis among experts retrospectively using videotaped 
examinations remains poor.
8




Hormone-stimulated pancreatic function tests (PFTs) to evaluate for EPI have long been considered the 
“nonhistological” reference standard for the diagnosis of chronic pancreatitis. Traditionally, these were 
performed by aspirating fluid from the small bowel after insertion of a double-lumen (Dreiling) 
collection tube.
10,11
  However, use of this tube has largely been replaced by endoscopic PFTs (ePFTs), 
which use intravenous sedation and a gastroscope to improve patient comfort.   Currently used ePFTs 
with secretin (sPFTs) collect duodenal fluid at timed intervals for at least 45 minutes after hormone 
administration
12 
and use a peak bicarbonate concentration (PBC) of ≤80 mEq/L to diagnosis EPI.
13
  
Secretin-stimulated ePFTs (sPFTs) provide similar accuracy to PFTs done with the Dreiling tube
14
 and 
demonstrate a sensitivity of 66% to 71% and specificity of 67% to 98% for the diagnosis of chronic 
pancreatitis.
15-17
   Hormone stimulation of pancreatic secretion may also produce variations in main 
pancreatic duct (MPD) compliance
18,19
, duodenal fluid volumes,
17
 and possibly sonographic changes in 
patients with or without chronic pancreatitis or EPI.  A small single-center study of 35 patients 
demonstrated that EUS morphologic evaluation of the pancreas with secretin stimulation (sEUS) and 
sPFTs can be performed safely simultaneously and MPD compliance may be greater in the pancreatic tail 
in normal subjects.
19
    
 In this prospective study, we hypothesized that EUS, sEUS and sPFTs in patients with suspected MCCP 
could be performed safely in a larger patient population.  Secondary objectives were to evaluate 
differences in duodenal fluid volumes, pancreatic sonographic features and main duct compliance.  
Finally, we sought to study the sequential impact of findings from EUS alone, sEUS changes and results 
of sPFTs on the suspected clinical diagnosis of MCCP and the test characteristics of the diagnosis of EPI 
compared with the EUS diagnosis of MCCP.  
 
Methods 
Patient Selection and Study Design 
The investigator-initiated protocol was originally intended to be a prospective multicenter study. 
However the Intuitional Review Board (IRB) at only one invited center (Indiana University Health 
Medical Center, Indianapolis) approved the protocol and supporting documents (ClinicalTrials.gov 
Identifier: NCT01997476, registered Nov 13, 2013).  After discussion with the senior investigator (T.G.), it 
was decided to continue as a single-center study.  Before enrollment, all patients underwent screening a 
medical history and physical examination to determine eligibility.  Eligible patients signed informed 
consent before enrollment.  Inclusion criteria included patients 18 to 80 years of age with clinical 
suspicion of chronic pancreatitis with or without EPI in whom ePFTs were planned for structural and 
functional evaluation of the exocrine pancreas.  They were also required to be capable of undergoing 
sedation and willing/capable of signing informed consent.  Exclusion criteria included severe 
cardiopulmonary or renal disease, ongoing illicit drug use/abuse, moderate to severe alcohol use (<30 
grams per day), pregnancy or nursing, known allergy to secretin, use of any medication within the 
previous 30 days that could cause pancreatitis or interfere with pancreatic function test interpretation, 
or use of an anticholinergic medication within 48 hours of enrollment. Patients were also excluded with 
previous pancreatic surgery or sphincterotomy, known pancreatolithiasis or pancreatic calcifications, 
suspected or proven sphincter of Oddi dysfunction, symptoms of acute pancreatitis within the previous 
60 days, a new abdominal pain or exacerbation of chronic pain within 30 days or presence of a condition 
which may interfere with exocrine pancreatic functioning including (celiac disease, type I diabetes, 
previous gastrectomy, cystic fibrosis, or severe malnutrition [BMI<18]). 
 
Combined EUS, e-PFT and sEUS Testing Procedure: 
All endoscopic procedures were performed by 1 of 3 experienced endosonographers using propofol 
sedation administered by an anesthesiologist. EGD was initially performed to exclude an alternative 
cause for symptoms.   An electronic radial EUS echoendoscope (Olympus GF-UE160-AL5; Olympus 
America; Center Valley Pa, USA) assessed for abnormal pancreatic parenchymal (hyperechoic foci ≥2 
mm, hyperechoic strands ≥3 mm, lobularity, cysts ≥3mm) and ductal (main duct irregularity, 
hyperechoic margins, shadowing stones and dilated side branches) findings in the head, body and tail.  
The baseline main pancreatic duct (B-MPD) diameter was measured in all 3 locations and recorded. 
Finally, the baseline anteroposterior (B-AP) diameter of the pancreas anterior to the splenoportal 
confluence was measured. The contents of the gastric and duodenal lumens were then aspirated 
completely by the echoendoscope and discarded. 
 
Synthetic human secretin (ChiRhoStim; ChiRhoClin Inc, Burtonsville, Md, USA) used for this study is 
supplied as 16 µg secretin, 1.5 mg of L-cysteine hydrochloride, and 20 mg of mannitol as a lyophilized 
powder per vial.  It was reconstituted in 8 mL of sterile NaCL such that each 1 mL of the resulting 
solution contains 2 µg of secretin.  At study commencement, a test dose of 0.2 µg (0.1mL) test dose was 
recommended before the full treatment dose to exclude an allergic reaction. If no allergic reaction was 
noted after one minute, the remaining full dose of secretin 0.2 µg/kg IV was given over 1 minute.   
During the study, FDA communication removed requirement and thereafter only the full 0.2 µg/kg IV 
secretin dose was given to remaining study patients.  
 
At 4, 8, and 12 minutes after secretin, real-time dynamic EUS measurement of the secretin-stimulated 
MPD (S-MPD) was re-measured in the head, body, and tail and any increase in prominence or visibility of 
parenchymal or ductal features compared with baseline was assessed.  Ten minutes after secretin, the 
anteroposterior (AP) gland diameter (S-AP) was also re-measured and evaluation of all parenchymal and 
ductal features were assessed for increased visibility or prominence.  After measurements, the 
echoendoscope was used to aspirate the gastric contents and any residual in the suction tubing were 
aspirated dry as well.  The gastroscope was then placed into the proximal duodenum at or distal to the 
major papilla.  At 15, 30, and 45 minutes after secretin, at least 3mLs of duodenal fluid was attempted to 
be collected through the suction channel of the gastroscope.  The procedure was then completed and 
the patient brought to recovery.  Duodenal collection samples were placed on ice and brought 
immediately to the hospital chemistry laboratory for evaluation of bicarbonate concentration using the 
hospital autoanalyzer.  No additional therapeutic maneuvers were performed during EUS to minimize 
confounding variables contributing to potential adverse events. 
 
The endoscopist performing the EUS rated the percent likelihood of chronic pancreatitis clinically at 3 
time points during the study: (1) after history, physical examination, and EUS but before secretin; (2) 
after secretin, repeat pancreatic duct and parenchymal measurements but before duodenal fluid 
collections, and (3) after all duodenal bicarbonate results were available. 
 
Definitions 
The highest bicarbonate concentration from the 3 samples was considered the peak concentration.  A 
peak bicarbonate concentration (PBC) ≥80 mEq/L from secretin ePFT was considered normal. Exocrine 
pancreatic insufficiency (EPI) was defined as all 3 bicarbonate values <80 mEq/L.  The EUS diagnosis of 
chronic pancreatitis (EUS-CP+) or absence of chronic pancreatitis (EUS-CP-) was defined as the presence 
of ≥5 parenchymal and/or ductal criteria or ≤4 criteria, respectively.
2,4
  Adverse events related to 
secretin administration and EUS were evaluated. These were classified as (1) expected versus 
unexpected; (2) serious adverse event versus important but not serious adverse event; (3) no 
reasonable possibility (where a medical condition or other cause for the event is identified); and (4) 
reasonable possibility. Serious adverse events were considered to be any undesirable sign, symptom, or 
medical condition that was fatal, life-threatening, required inpatient hospitalization ≥24 hours, resulted 
in persistent or significant disability/incapacity, or was medically significant and which the investigator 
regarded as serious based on clinical judgement. 
 
Statistical Analysis 
Based on previous studies using ERCP as a reference standard, we estimated that the sensitivity and 
specificity of EUS using ≥5 features of chronic pancreatitis for the detection of EPI was at least 70% and 
80%, respectively.  Based on these assumptions, enrollment of 800 patients would permit estimation of 
sensitivity and specificity with confidence limits of 10%.  As only one study center (Indiana University 
Health Medical Center, Indianapolis) approved the protocol and supporting documents, it was decided 
to continue at that single center study with a suggested enrollment of about 150 patients. This 
enrollment size is the value that would have been expected from each center recruited from the study 
outset should approval from all IRBs have been possible. 
Analyses were performed to determine associations between outcomes of interest for 2 population 
groups: (1) Normal exocrine pancreatic function versus  EPI and; (2) ≥5 EUS features of chronic 
pancreatitis (EUS-CP+) vs. ≤4 features of chronic pancreatitis (EUS-CP-).  Student t-tests were used to 
compare continuous variables between groups and Chi-Square tests were used to analyze homogeneity 
between groups for categorical variables. The Fisher exact test were used to verify the results if 
numerical values were small.  Correlation analyses were performed when analyzing the association 
between outcome variables of interest, when all were continuous.  When data were nonlinear, 
nonparametric tests were performed, using the Wilcoxon rank sum test and Spearman’s correlation 
analysis.  All analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA). 
Results 
Study Population and Dynamic EUS Measurements 
Between December 2013 and November 2017, 169 consecutive patients were evaluated and 5 failed 
screening due to refusal to take a pregnancy test (n=1), BMI<18 (n=1), previous RYGBP (n=1), use of 
sandostatin (n=1) and diagnosis of acute pancreatitis (n=1).  Of the 164 patients consented, 19 were 
dropped due to discovery of a pancreatic cyst (suspected IPMN) or solid mass requiring biopsy (n=6), 
gastric bezoar (n=3), prolonged hypoxia or difficulty with sedation (n=3), inability to complete the 
procedure due to time constraints or other emergency procedure (n=3), failure to maintain a working IV 
(n=1), identification of fatty pancreas with nonvisible pancreatic duct (n=1), autoimmune pancreatitis 
(n=1) and pancreatic calcifications precluding further evaluation of features of chronic pancreatitis 
(n=1).  
The remaining 145 patients (mean age: 44 ± 14 years; 98F) were diagnosed with EPI (n=32; 22%) or 
normal exocrine pancreatic function (n=131, 78%).  The EPI group had a more frequent diagnosis of 
diabetes (44%) compared those without EPI (16%; p=0.009, Table 1A).  Baseline demographics and the 
frequency of EUS-CP+ (34% vs 32%; p=0.75) were otherwise similar (Table 1B). The ratio of the secretin 
stimulated main pancreatic duct (S-MPD) to baseline (B-MPD) measurements (S-MPD/B-MPD) in the tail 
at 4 (p=0.01) and 8 (p=0.02) minutes after secretin were higher in patients with normal exocrine 
function but were similar at other times and sites in the pancreas. Duodenal fluid quantities aspirated at 
all 3 times were also similar between the 2 groups. In 18 patients, the diagnosis of normal exocrine 
pancreatic function was made only after the 45-minute collection.  
 
Using ≥5 EUS criteria as diagnostic for chronic pancreatitis, 47 out of 145 (32%) were EUS-CP+ whereas 
the remaining 98 out of 145 (68%) were EUS-CP- (≤4 EUS criteria).  Baseline demographics, frequency of 
EPI, mean S-MPD/B-MPD at all sites and times, mean S-AP/B-AP and duodenal fluid quantities aspirated 
at all 3 times were also similar between the 2 groups (Table 1B).  
 
Assessment of Parenchymal and Ductal Features after Secretin 
During evaluation 10 minutes after secretin, those with normal exocrine pancreatic function (Table 2A) 
had more visible parenchymal hyperechoic foci (p=0.023), hyperechoic strands (p=0.019) and echogenic 
main pancreatic duct walls (p=0.002) compared with the EPI group. The remaining parenchymal and 
ductal changes and the AP gland diameter was similar between the 2 groups.  For the EUS-CP+ group, 
mean gland AP diameter (p=0.03), parenchymal lobularity (p=0.01) and duct sidebranches (p=0.03) were 
more visible after secretin compared with the EUS-CP- group (Table 2B).  The remaining features were 
similar between the 2 groups. 
 
Endoscopist Clinical Assessment of Likelihood of Chronic Pancreatitis 
There were 21 (14%) patients with EPI and EUS-CP- and 77 (53%) with normal exocrine function and 
EUS-CP-. The remaining were 11 (8%) with EPI and EUS-CP+ and 36 (25%) with normal exocrine function 
and EUS-CP+.  The clinical assessment of the percent likelihood in of chronic pancreatitis in all 4 groups 
all 3 time points evaluated is shown in Table 3.  For all groups, there was a statistically significant change 
in the median percent likelihood before, during and after secretin administration.  
  
Performance of Pancreatic Function Testing for the EUS diagnosis of Chronic Pancreatitis 
There was no association between the number of EUS criteria identified and the frequency of EPI 
(p=0.94, Table 4).  For the 47 EUS-CP+ patients, 11 (23%) had EPI and 36 (77%) had normal exocrine 
function.  For the 98 EUS-CP- patients, 21 (21%) had EPI and 77 (79%) had normal exocrine function.  
The diagnosis of EPI had a sensitivity, specificity, positive and negative predictive value and accuracy of 
23.4% (95% CI, 12.3-38.0), 78.6% (95% CI, 69.1-86.2), 34.4% (95% CI, 21.6-49.9), 68.1% (95% CI, 63.9-
72.1), and 60.7 (95% CI, 52.2-68.7), respectively for the EUS diagnosis of chronic pancreatitis using ≥ 5 
criteria (EUS-CP+).  
 
If ≥4 criteria were used for the EUS diagnosis of chronic pancreatitis, there were 67 EUS CP+ patients 
including 14 (21%) with EPI and 53 (79%) with normal exocrine function.  For the 78 EUS-CP- patients, 18 
(23%) had EPI and 60 (77%) had normal exocrine function. When ≥4 criteria were used, the diagnosis of 
EPI had a sensitivity, specificity, positive and negative predictive value, and accuracy of 20.9% (11.9-
32.6), 76.9% (66.0-85.7), 43.8% (29.6-59.1), 53.1% (48.8-57.3) and 51.0% (42.6-59.4), respectively for the 
diagnosis of chronic pancreatitis.  
 
Adverse Events 
Three of the 169 (1.7%) consented patients had repeated or prolonged hypoxia requiring early 
termination of the procedure and were therefore excluded from data analysis. None of the 3 required 
application of positive pressure ventilation and were classified as expected, important but not serious 
adverse events  
 
Discussion 
In the current study, we found that same session EUS morphologic evaluation, dynamic measurement of 
MPD compliance (sEUS) and collection of duodenal fluid (sPFTs) were feasible and safe in a large 
prospective single center cohort. These results confirm findings of a previous smaller study.
19
  
Furthermore, parenchymal and ductal findings from sEUS and duodenal bicarbonate findings from ePFTs 
had a significant impact on the clinical diagnosis of chronic pancreatitis in patients with and without 
EUS-CP (≥5 features). To our knowledge, this is the first prospective evaluation of the impact of ePFT 
findings on the clinical suspicion of chronic pancreatitis in these patients. 
 
Administration of secretin and resultant increase in pancreatic fluid secretion would theoretically 
increase MPD diameter in and duodenal fluid volume in normal subjects.   MPD compliance
20-22
 and 
duodenal (pancreatic) fluid volume measurements
17,23
 after secretin have therefore been evaluated as 
alternative measures for exocrine pancreatic function.  Gardner et al
19
 found that duct compliance 
measured by EUS was higher in the pancreatic tail after secretin in normal subjects.  Similarly, we found 
that the duct compliance (S-MPD/B-MPD) was higher in the pancreatic tail at 4 and 8 minutes (but not 
12 minutes) after secretin in those with normal exocrine function compared with the EPI group.  
However, there was no difference in duct compliance in the head or body at any time after secretin 
between these 2 groups and also no difference in duct compliance in the head, body or tail in the EUS-
CP+ compared the EUS-CP- group.   Furthermore, duodenal volumes aspirated at 15, 30 and 45 minutes 
after secretin were the same in all groups.   These findings suggest that EUS measurement of duct 
compliance and duodenal volumes after secretin may not be useful for the diagnosis of EPI or chronic 
pancreatitis.  
 
Early research noted that output from the pancreas peaked 30 minutes after hormone stimulation.
24-26
 
Thus, sampling from duodenal fluid by the Dreiling tube to test physiologic function typically occurred 
up to 60 minutes after stimulation.
27,28
  Current variations of ePFTs include testing only up to 45 minutes 
after secretin
12
 or administering secretin 30 minutes before sedation for endoscopy.
17
 In the current 
study, the first collection occurred 15 minutes after sedation in order to complete EUS morphologic 
evaluation after secretin (sEUS exam) but continued to 45 minutes to ensure that PBC is approximated. 
We found that in 18 patients, the diagnosis of normal exocrine function was made only by the results of 
the 45-minute collection, which confirm the necessity of this timed collection during ePFTs.  
 
Because MRI with IV contrast may produce or detect abnormalities such as signal differences on T1 
imaging, gland atrophy and irregular outer margins
23,29
, we postulated that the pancreatic duct and 
parenchyma may produce sonographic changes after secretin.  In patients with normal exocrine 
function, post-secretin imaging showed parenchymal hyperechoic foci and strands and MPD echogenic 
walls were more visible compared with the EPI group. For the EUS-CP+ group, parenchymal lobularity 
and duct sidebranches were more visible after secretin compared with the EUS-CP- group.   These 
findings may represent sonographic imaging of increased fluid secretion from ductal cells but as noted 
above these changes did not generally translate into differences in duct compliance or duodenal 
volumes sampled in patients with or without EPI or EUS-CP. 
 
The development of pancreatic fibrosis in alcoholics appears to be patchy and may develop before the 
clinical onset of chronic pancreatitis.
30
 This preclinical stage of pancreatic disease before chronic 
pancreatitis has been termed pancreatopathy
31
 and may manifest histology as parenchymal atrophy and 
acinar cell loss.  The absence of clinical symptoms may eventually lead to minimal-change chronic 
pancreatitis (MCCP) which is chronic pancreatitis in patients with abdominal pain but equivocal or 
absent related imaging findings.
32
 The findings of histology in evaluation of pancreatic disease is usually 
impractical unless patients undergo surgery or preoperative biopsy.
33
 Therefore, we attempted to use 
both EUS and sPFTs to identify patients with MCCP.  Previous studies evaluating sPFTs demonstrate a 
sensitivity of 66% to 71% and specificity of 67-98% for the diagnosis of chronic pancreatitis (Table 5) 




 or clinical consensus.
17
   We 
found that the diagnosis of EPI had a sensitivity, specificity and accuracy of 23.4%, 78.6% and 60.7%, 
respectively compared with the EUS diagnosis of chronic pancreatitis using ≥5 criteria (EUS-CP+).  If only 
≥4 criteria, the diagnosis of EPI had a sensitivity, specificity and accuracy of 20.9%, 76.9% and 51.0%, 
respectively.  For the current study, we estimated that the sensitivity and specificity of EUS using ≥5 
features of chronic pancreatitis for the detection of EPI was at least 70% and 80%, respectively when 
using ERCP as a reference standard.   Our  findings are significantly lower than previously reported and 
likely explained by overdetection and mislabeling of abnormal parenchymal and ductal features in 
normal patients or those with MCCP and the lack of inclusion of patients with advanced disease.  This 
phenomenon has also been described for interpretation of pancreatograms during ERCP.
34
    A recent 
study highlighted the difficulty of EUS in the evaluation of histology findings in noncalcific chronic 
pancreatitis.  Trikudanathan et al
32
 found that compared with histology before total pancreatectomy 
and islet autotransplantation (TPIAT), identification of ≥4 EUS chronic pancreatitis features within 1 year 
of surgery showed a sensitivity, specificity and accuracy of 61%, 75%, and 63% for the histologic 
diagnosis of chronic pancreatitis.  These data along with the current study suggest that use of EUS alone 
for the diagnosis of MCCP should be discouraged and instead used along with direct testing for EPI such 
as ePFTs. In our study, findings from ePFTs did increase the clinical diagnosis of chronic pancreatitis in all 
subgroups evaluated.   A normal EUS exam alone may be sufficient alone to exclude chronic pancreatitis 
whereas findings of advanced disease (pancreatolithiasis and calcifications) is sufficient to confirm the 
diagnosis. 
 
We found that in EUS-CP+ and EPI were diagnosed concomitantly in 11 (8%) patients whereas EUS-CP- 
and normal exocrine function were found concomitantly in 77 (53%) patients, which led to median final 
certainties of chronic pancreatitis of 90% and 0%, respectively.   The remaining 57 (39%) patients had 
discordant findings between EUS and sPFT results which led to difficulty and wide-ranging certainties for 
the clinical diagnosis of chronic pancreatitis. It is crucial that endoscopists who perform EUS and ePFTs 
are aware of these possible discrepancies and how they may impact clinical management. Further 
research is required to evaluate the test characteristics of EPI for the diagnosis of chronic pancreatitis 
using other gold standards besides EUS findings.     
 
Our study is the first to prospectively evaluate sonographic findings of chronic pancreatitis after secretin 
and the impact of sEUS and ePFT findings on the subsequent clinical diagnosis.  Nevertheless, our study 
does have 3 principal limitations. First, the study population was smaller than designed because IRB 
approval was only able to be obtained at one of the original participating institutions.  Thus, study 
findings must be interpreted with caution as the sample size was only about one-fifth of the intended 
figure of 800 based on power calculations. However, this study is still the largest study to date the 
prospectively evaluates ePFTs and EUS and used 3 different endosonographers.  We believe it is unlikely 
that this study will be replicated in a larger group.   The second limitation is the use of EUS features of 
chronic pancreatitis as the gold standard for the diagnosis of chronic pancreatitis. Although other 
studies have used histology, clinical follow-up, or ERCP and MRCP findings, our study design in patients 
with MCCP did not permit use of other surrogate tests.   Finally, interpretation of pancreatic duct and 
parenchymal effects of secretin was not performed by endosonographers blinded to the previous 
ultrasound findings.     ‘ 
 
In conclusion, same session EUS and ePFTs are safe and feasible. Secretin causes distinct sonographic 
changes in patients with normal exocrine function and EUS evidence of chronic pancreatitis but dynamic 
MPD ratios and duodenal volumes aspirated after secretin do not appear useful for the diagnosis of EPI. 
Findings from sEUS and ePFTs have a significant impact in the clinical assessment chronic pancreatitis in 
patients with and without EUS-CP but ePFT results show poor correlation to the EUS diagnosis of chronic 
pancreatitis.  Finally, a 45-minute ePFT collection is required to confirm the diagnosis of normal exocrine 
function.  Further studies, particularly in those with suspected MCCP are required to evaluate the role of 
EUS and ePFTs.  
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Table 1A:  Baseline Demographic and Clinical Data and Results of Dynamic EUS Measurements and 
Pancreatic Fluid Collection Before and After Secretin for the 145 patients with Exocrine Pancreatic 










Mean Age (SD) 44.0 (13.5) 47.8 (13.6) 43.0 (13.3) 0.07 
Female (n, %) 98 (68.1) 24 (75.0) 74 (66.1) 0.34 
Median (range) BMI (kg/m
2
 ) 26.3 (15.2 – 52.3) 29.1 (19.1 – 40) 25.9 (15.2 – 52.3) 0.09 
Tobacco User (n, %) 59 (41.0) 15 (46.9) 44 (39.3) 0.44 
Alcohol (n, %) 17 (11.8) 4 (12.5) 13 (11.6) 0.89 
Diabetic (n. %) 32 (22.2) 14 (43.8) 18 (16.1) 0.0009 
Number of EUS features for 
chronic pancreatitis (n, %) 
 ≤4 98 (67.6) 21 (65.6) 77 (68.1) 
0.79 
 ≥5 47 (32.4) 11 (34.4) 36 (31.9) 
Mean (SD) S-MPD/B-MPD 
   Head at 4 minutes 1.30 (1.19) 1.28 (0.33) 1.30 (1.34) 0.87 
   Body at 4 minutes 1.35 (0.43) 1.34 (0.44) 1.36 (0.42) 0.83 
   Tail at 4 minutes 1.31 (0.47) 1.12 (0.37) 1.36 (0.49) 0.01 
   Head at 8 minutes 1.31 (1.36) 1.21 (0.29) 1.33 (1.53) 0.41 
   Body at 8 minutes 1.25 (0.40) 1.29 (0.55) 1.24 (0.35) 0.59 
   Tail at 8 minutes 1.32 (0.46) 1.18 (0.32) 1.36 (0.49) 0.02 
   Head at 12 minutes 1.32 (0.62) 1.26 (0.31) 1.33 (1.82) 0.67 
   Body at 12 minutes 1.24 (0.40) 1.25 (0.40) 1.24 (0.40) 0.85 
   Tail at 12 minutes 1.28 (0.42) 1.23 (0.40) 1.29 (0.43) 0.44 
Mean (SD) S-AP diameter/ 
B-AP diameter 
1.05 (0.65) 1.03 (0.17) 1.06 (0.73) 0.67 
Mean (SD) HC03 (mmol/L) at 15 
minutes 
75.1 (18.3) 57.1 (16.8) 80.2 (15.3) <.0001* 
Mean (SD) HCO3 (mmol/L) at 30 
minutes 
80.9 (19.7) 59.2 (19.1) 87.1 (14.9) <.0001* 
Mean (SD) HCO3 (mmol/L) at 45 
minutes 
82.3 (18.3) 58.8 (17.4) 89.0 (11.9) <.0001* 
Mean (SD) Volume (mL) 
duodenal fluid at 15 minutes 
11.8 (6.4) 13.1 (7.6) 11.4 (6.0) 0.18 
Mean (SD) Volume (mL) 
duodenal fluid at 30 minutes 
11.9 (6.3) 11.3 (6.3) 12.1 (6.3) 0.49 
Mean (SD) Volume (mL) 
duodenal fluid at 45 minutes 
10.9 (7.3) 11.3 (8.7) 10.8 (6.9) 0.71 
Abbreviations:  EUS: endoscopic ultrasound; BMI: body mass index; MPD: main pancreatic duct;  HC03: bicarbonate 
Footnote:  Exocrine pancreatic insufficiency (EPI) was defined as all bicarbonate values <80 mEq/L. Normal 
exocrine pancreatic function had at least one value >80mEq/L. The EUS diagnosis of chronic pancreatitis 
(EUS-CP+) or absence of CP (EUS-CP-) was defined as the presence of ≥5 parenchymal or ductal criteria or 
≤4 criteria, respectively.  
 
Table 1B:  Baseline Demographic and Clinical Data and Results of Dynamic EUS Measurements and 
Pancreatic Fluid Collection Before and After Secretin for the 145 patients with EUS evidence of chronic 






Mean (SD) Age 44 (14.5) 44 (13.0) 0.99 
Female (n, %) 30 (65.2) 68 (69.4) 0.62 
Median (range) BMI (kg/m
2
) 26.6 (17.3 – 52.3) 26.2 (15.2 – 47.1) 0.88 
Tobacco User (n, %)  22 (47.8) 37 (37.8) 0.25 
Alcohol (n, %) 6 (13.0) 11 (11.2) 0.75 
Diabetic (n. %) 10 (21.7) 22 (22.5) 0.92 
Exocrine Pancreatic  
Insufficiency (n, %) 
11 (23.4) 21 (21.4) 0.79 
Mean (SD) 
S-MPD/B-MPD 
   
   Head at 4 min 1.2 (0.3) 1.4 (1.4) 0.31 
   Body at 4 min 1.3 (0.4) 1.4 (0.4) 0.26 
 Tail at 4 min 1.3 (0.5) 1.3 (0.5) 0.30 
 Head at 8 min 1.4 (0.3) 1.3 (1.7) 0.60 
 Body at 8 min 1.3 (0.4) 1.2 (0.4) 0.39 
 Tail at 8 min 1.4 (0.5) 1.3 (0.5) 0.39 
 Head at 12 min 1.2 (0.3) 1.4 (2.0) 0.46 
 Body at 12 min 1.27 (0.4) 1.23 (0.4) 0.52 
 Tail at 12 min 1.33 (0.4) 1.3 (0.5) 0.32 
Mean (SD) S-AP diameter/ 
B-AP diameter
1.02 (0.1) 1.07 (0.8) .053 
Mean (SD) HC03 (mmol/L) 
at 15 minutes 
74.70 (21.8) 75.3 (16.5) 0.88 
Mean (SD) HCO3 (mmol/L) 
at 30 minutes 
81.15 (23.4) 80.7 (17.8) 0.93 
Mean (SD) HCO3 (mmol/L) 
at 45 minutes 
80.04 (22.1) 83.42 (16.1) 0.35 
Mean (SD) Volume (mL) 
duodenal fluid at 15 minutes 
12.26 (6.2) 11.51 (6.5) 0.51 
Mean (SD) Volume (mL) 
duodenal fluid at 30 minutes 
12.26 (6.4) 11.79 (6.3) 0.68 
Mean (SD) Volume (mL) 
duodenal fluid at 45 minutes 
11.06 (6.1) 10.81 (7.9) 0.84 
Abbreviations:  EUS: endoscopic ultrasound; BMI: body mass index; MPD: main pancreatic duct;  HC03: bicarbonate 
Exocrine pancreatic insufficiency (EPI) was defined as all bicarbonate values <80 mEq/L. Normal exocrine pancreatic 
function had at least one value >80mEq/L.  The EUS diagnosis of chronic pancreatitis (EUS-CP+) or absence of CP 
(EUS-CP-) was defined as the presence of ≥5 parenchymal or ductal criteria or ≤4 criteria, respectively. 
Table 2A:  EUS Pancreatic Parenchymal and Ductal Changes after Human Secretin in Patients with 
and without Exocrine Pancreatic Sufficiency and Exocrine Pancreatic Insufficiency 
Exocrine pancreatic 
insufficiency (n=32) 
Normal exocrine pancreatic 
function (n=113) P value 
 Increased Parenchymal Features 
 Visible After Secretin (n, %) 
 Hyperechoic Foci 12 (38) 68 (60) 0.023 
 Hyperechoic Strands 13 (41) 72 (64) 0.019 
 Cysts 1 (3) 2 (2) 0.53 
 Lobularity 1 (3) 9 (8) 0.46 
 Increased Ductal Features 
 Visible After Secretin (n, %) 
 Hyperechoic walls 4 (13) 48 (43) 0.002 
 Sidebranches 11 (34) 39 (35) 0.99 
 Diameter 1 (3) 2 (2) 0.53 
 Irregularity 0 (0) 0 (0) n/a 
 Stones 1 (3.1) 0 (0) 0.22 
 Mean (SD) AP diameter (mm) 15.8 (3.1) 15.9 (3.7) 0.79 
Definitions: 
Exocrine pancreatic insufficiency (EPI) was defined as all bicarbonate values <80 mEq/L. 
Normal exocrine pancreatic function had at least one value >80mEq/L 
Table 2B: EUS Pancreatic Parenchymal and Ductal Changes After Secretin in Patients with EUS-CP+ (≥5 






 Increased Parenchymal Features 
 Visible After Secretin (n, %) 
 Hyperechoic Foci 26 (55) 54 (55) 0.98 
 Hyperechoic Strands 28 (60) 57 (58) 0.87 
 Cysts 0 (0) 3 (3) 0.55 
 Lobularity 7 (15) 3 (3) 0.01 
 Increased Ductal Features 
 Visible After Secretin (n, %) 
 Hyperechoic Margins 20 (43) 32 (33) 0.26 
 Dilated Sidebranches 22 (47) 28 (29) 0.03 
 Diameter 1 (2) 2 (2) 1.0 
     Main duct irregularity 0 (0) 0 (0) n/a 
     Intraductal Stones 0 (0) 1 (1) 1.0 
















Table 3:  Endoscopist Assessment of Percent Certainty of Chronic Pancreatitis (CP) Pre-secretin, Post- 
Secretin and After Duodenal Bicarbonate Results (Final Certainty) in Patients with Exocrine Pancreatic 
Insufficiency (EPI), Normal Exocrine Pancreatic Function and EUS criteria with (EUS-CP+) or without 










Certainty of CP      
(%, range) 
Median Final 
Certainty of CP 




EUS-CP(-) and EPI 
(n=21) 
0 
(0 – 50) 
20 
(0 – 50) 
70 
(20 – 100) 
0.009 










EUS-CP(+) and EPI 
(n=11) 
60 
(20 – 100) 
60 
(20 – 100) 
90 
(80 – 100) 
.023 




(15 – 100) 
57.5 





Note:  The endoscopist performing the EUS rated the percent likelihood of CP clinically at 3 time points 
during the study: 1) Pre secretin:  after history, physical exam and EUS but before secretin 
administration; 2) Post Secretin/Pre-sPFTs: After secretin administration with repeat pancreatic duct and 
parenchymal sonographic assessment but before timed duodenal fluid collections and; 3) Final:  after all 
duodenal bicarbonate results were available. 
 
Abbreviations:   EUS – endoscopic ultrasound; HC03-  bicarbonate;   PPV- positive predictive value;  NPV 
– negative predictive value 
 
Definitions:  
Exocrine Pancreatic Insufficiency (EPI):  Peak Bicarbonate Concentration <80mEq/L  
Normal exocrine pancreatic function: Peak Bicarbonate Concentration ≥80mEq/L 
EUS findings of Chronic Pancreatitis (EUS-CP+): ≥5 criteria. 
EUS findings of no Chronic Pancreatitis (EUS-CP -):  <4 criteria  
Table 4: Relationship between Number of EUS Criteria for Chronic Pancreatitis for the 145 patients with 













Number of EUS criteria for 
the Diagnosis of Chronic 
Pancreatitis (n, %) 
    
0 13 (9.0) 3 (9.4) 10 (8.9) 
.9367 
1 4 (2.8) 2 (6.3) 2 (1.8) 
2 25 (17.2) 5 (15.6) 20 (17.7) 
3 36 (24.8) 8 (25.0) 28 (24.8) 
4 20 (13.8) 3 (9.4) 17 (15.0) 
5 30 (20.7) 7 (21.9) 23 (20.4) 
6 11 (7.8) 3 (9.4) 8 (7.1) 
7 5 (3.5) 1 (3.1) 4 (3.5) 
8 0 (0) 0 (0) 0 (0) 
9 1 (0.7) 0 (0) 1 (0.9) 
Definitions:  
Exocrine Pancreatic Insufficiency (EPI):  Peak Bicarbonate Concentration <80mEq/L 
Normal exocrine pancreatic function: Peak Bicarbonate Concentration ≥80mEq/L 
Figure 1: Endoscopist Assessment of Percent Certainty of the Clinical Diagnosis of Chronic Pancreatitis 
(CP) at 3 different time points: pre-secretin, post-secretin and after duodenal bicarbonate results (final) 
in patients with EUS-CP+ (≥5 criteria), EUS-CP- (≤4 criteria), Exocrine Pancreatic Insufficiency and 
Exocrine Pancreatic Sufficiency 
Definitions:  
Exocrine Pancreatic Insufficiency (EPI):  Peak Bicarbonate Concentration <80mEq/L 
Normal exocrine pancreatic function: Peak Bicarbonate Concentration ≥80mEq/L 
EUS findings of Chronic Pancreatitis (EUS-CP+): ≥5 criteria. 
EUS findings of no Chronic Pancreatitis (EUS-CP -):  <4 criteria  
Table 5:  Published Studies Evaluating the Test Characteristics of Endoscopic Pancreatic Function Tests (ePFTs) with Secretin for the Diagnosis of 

























































15, 30, 45 ≥5 EUS criteria  23.4 78.6 34.4 68.1 60.7 
 
Note: All studies cited use a Peak Bicarbonate Concentration <80mEq/L for the Diagnosis of Exocrine Pancreatic Insufficiency 
Abbreviations: ePFTs:  endoscopic pancreatic function tests;  EUS – endoscopic ultrasound;  HC03-  bicarbonate;   PPV- positive predictive value;  
NPV – negative predictive value 

Acronyms 
AP: anteroposterior  
BMI: body mass index   
ePFTs: endoscopic pancreatic function tests 
EPI: exocrine pancreatic insufficiency  
EUS: endoscopic ultrasound  
EUS-CP+:  EUS diagnosis of chronic pancreatitis 
EUS-CP-:  absence of EUS diagnosis of chronic pancreatitis 
MPD: main pancreatic duct;   
HC03: bicarbonate 
MCCP:  minimal-change chronic pancreatitis  
MRI: magnetic resonance imaging 
PBC: peak bicarbonate concentration 
RYGBP: Roux-en-Y gastric bypass 
sPFTs: secretin stimulated endoscopic pancreatic function tests 
S-MPD/B-MPD: secretin main pancreatic duct diameter/baseline main pancreatic duct diameter
SAE: serious adverse event 
